Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : Correction to Johnson & Johnson Jury Story

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/21/2019 | 01:38pm EDT

"NY Jury Delivers $25M Judgment Against Johnson & Johnson -Bloomberg," at 1:26 p.m. ET incorrectly reported the amount of the payment in the first paragraph. A New York jury said Johnson & Johnson (JNJ) must pay $25 million to a woman who claims she got cancer by using the company's products, Bloomberg reports Tuesday.

This article is part of a news chaine.
Article 2 / 2
<< Preceding Next >>
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
06/14JOHNSON & JOHNSON : Janssen Says Guselkumab Psoriatic Arthritis Studies Meet End..
DJ
06/14JOHNSON & JOHNSON : New data from Janssen presented at the Annual European Congr..
AQ
06/12JOHNSON & JOHNSON : Judge orders Johnson & Johnson, Colgate to pay $10M in cance..
AQ
06/12COLGATE PALMOLIVE : J&J, Colgate-Palmolive Ordered to Pay Nearly $10 Million in ..
DJ
06/12MARKETS RIGHT NOW : Stocks fall for the 2nd day in a row
AQ
06/12JOHNSON & JOHNSON : Janssen Pharmaceutical - INVOKANA Significantly Reduced Majo..
AQ
06/12MARKETS RIGHT NOW : US stocks are mixed in early trading
AQ
06/12MEDCOLCANNA ORGANICS : Strengthens Board of Directors with Addition of Pharmaceu..
AQ
06/12GENMAB : J&J bags $150M option on Genmab's Darzalex successor
AQ
06/11JOHNSON & JOHNSON : Genmab, Janssen in Cancer-Drug Licensing Deal
DJ
More news
Financials ($)
Sales 2019 81 218 M
EBIT 2019 25 617 M
Net income 2019 19 737 M
Debt 2019 8 610 M
Yield 2019 2,71%
P/E ratio 2019 19,49
P/E ratio 2020 17,71
EV / Sales 2019 4,64x
EV / Sales 2020 4,25x
Capitalization 368 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Average target price 149 $
Spread / Average Target 7,4%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON8.55%348 981
PFIZER-2.04%233 072
ROCHE HOLDING LTD.13.39%227 848
NOVARTIS20.35%220 893
MERCK AND COMPANY8.34%206 641
ELI LILLY AND COMPANY-3.44%113 364